Skip to main content

Table 2 Baseline characteristics of the patients who developed Pneumocystis pneumonia a

From: Prophylaxis for Pneumocystis pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study

Patient Biologic Age (years) Sex RA duration (months)b Treatment duration (months)c Pulmonary disease DM DAS28 score (ESR) PSL (mg) KL-6 (U/ml)
1 IFX 71 Female 72 10 (-) (-) 6.24 2.5 ND
2 IFX 78 Female 79 1 (+) (-) 6.99 1.0 178
3 IFX 62 Male 21 20 (+) (-) 7.40 2.0 893
4 IFX 78 Female 40 1 (+) (-) 8.04 8.0 398
5 IFX 57 Male 5 2 (+) (-) 3.38 0 304
6 ETN 73 Male 2 3 (+) (-) 7.20 50 366
7 ETN 59 Female 252 15 (-) (-) 5.60 1.0 224
8 ETN 75 Male 132 5 (+) (-) 6.75 5.0 624
9 TCZ 73 Male 84 8 (+) (-) 7.00 10 445
Mean   69.5   76.3 7.2 7/9 0/9 6.51 8.83 429
  1. aPCP developed in nine patients who did receive trimethoprim/sulfamethoxazole prophylaxis. Eight of nine patients were given glucocorticoids. -: Without DM; +: With DM; DAS28: Disease Activity Score in 28 joints; DM: Diabetes mellitus; ESR: Erythrocyte sedimentation rate; ETN: Etanercept; IFX: Infliximab; PCP: Pneumocystis pneumonia; PSL: Prednisolone; RA: Rheumatoid arthritis; TCZ: Tocilizumab. bRA duration was measured between the onset of RA and the initiation of biologics. cTreatment duration was measured between the initiation of biologics and PCP development.